Pharmacotherapy in pediatric obesity: current agents and future directions.
Childhood obesity is emerging as a major public health threat, with adverse implications on the health of individuals and long-term costs to society. Family-based lifestyle interventions with behavioral modification, diet and exercise form the mainstay of treatment. Pharmacologic treatment may be considered in selected subjects, especially in the presence of significant and severe comorbidities, when lifestyle intervention has failed to achieve weight reduction. Orlistat and sibutramine are FDA-approved for treatment of pediatric obesity; metformin may be considered in the presence of clinically significant insulin resistance. Evidence is lacking on the appropriate duration of medical therapy and optimal combination with lifestyle intervention. Lack of coverage of medications by insurance and high out-of-pocket costs may be limiting factors to some families. Adverse effects necessitate careful monitoring and may lead to discontinuation of medication. Pharmacologic agents with novel mechanisms of action offer hope of improved efficacy, tolerability and safety.
Wald
Abigail B
AB
Division of Pediatric Endocrinology, UH Rainbow Babies & Children's Hospital, Case Western Reserve University, 11100 Euclid Avenue, RB&C Suite 737, Cleveland, OH 44106, USA.
Uli
Naveen K
NK
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D002648:Child; D003503:Cyclobutanes / Q000627:therapeutic use; D004358:Drug Therapy / Q000379:methods* / Q000639:trends*; D006801:Humans; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D008687:Metformin; C058254:sibutramine
Obes Res. 2002 Jul;10(7):633-41
12105285
J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6
15472169
Ann Intern Med. 2006 Jul 18;145(2):81-90
16847290
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001872
19160202
N Engl J Med. 2007 Dec 6;357(23):2371-9
18057339
N Engl J Med. 2007 Dec 6;357(23):2329-37
18057335
Clin Ther. 2006 May;28(5):770-82
16861099
Pediatrics. 2001 Apr;107(4):E55
11335776
J Pediatr. 2008 Jun;152(6):817-22
18492523
J Clin Endocrinol Metab. 2008 Dec;93(12):4576-99
18782869
J Clin Endocrinol Metab. 2003 Jun;88(6):2586-92
12788859
Diabetes Care. 2005 May;28(5):1083-91
15855571
Arch Fam Med. 2000 Feb;9(2):160-7
10693734
Pediatrics. 2007 Dec;120 Suppl 4:S254-88
18055654
J Clin Endocrinol Metab. 2005 Mar;90(3):1460-5
15613431
Obes Res. 2002 Oct;10(10):1049-56
12376586
Eur J Pediatr. 2004 Dec;163(12):738-41
15378354
Diabetes Care. 2007 Feb;30(2):395-402
17259519
Acta Paediatr. 2003 Jun;92(6):666-70
12856974
JAMA. 2006 Apr 5;295(13):1549-55
16595758
JAMA. 2005 Jun 15;293(23):2873-83
15956632
J Clin Psychiatry. 2007 Sep;68(9):1324-32
17915969
Pediatr Diabetes. 2008 Dec;9(6):567-76
18761646
JAMA. 2003 Apr 9;289(14):1805-12
12684359
Endocr Pract. 2006 Jan-Feb;12(1):18-28
16524859
JAMA. 2008 May 28;299(20):2401-5
18505949
J Clin Endocrinol Metab. 2006 Jun;91(6):2074-80
16595599
J Clin Endocrinol Metab. 2008 Dec;93(12):4600-5
18782881
Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):37-47
18185061
Diabetes Care. 2005 May;28(5):1092-100
15855572
J Pediatr Endocrinol Metab. 2004 Mar;17(3):307-19
15112907
N Engl J Med. 2005 Nov 17;353(20):2121-34
16291982
Metabolism. 2001 Dec;50(12):1457-61
11735093
JAMA. 2006 Feb 15;295(7):761-75
16478899
Obes Res. 2002 Jul;10(7):642-50
12105286
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44
19285266
J Clin Endocrinol Metab. 2005 Mar;90(3):1871-87
15598688
Pediatrics. 2007 Dec;120 Suppl 4:S164-92
18055651
J Pediatr. 2004 Dec;145(6):744-9
15580194
J Child Neurol. 2000;15 Suppl 1:S22-6
11218053
Lancet. 1998 Jul 18;352(9123):167-72
9683204
JAMA. 2003 Apr 9;289(14):1820-5
12684361